Cover Image
市場調查報告書

特發性肺纖維化 (IPF):流行病學、病患人數的市場預測、治療流程、上市藥及開發平台藥物分析

Idiopathic pulmonary fibrosis: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365208
出版日期 內容資訊 英文 192 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
特發性肺纖維化 (IPF):流行病學、病患人數的市場預測、治療流程、上市藥及開發平台藥物分析 Idiopathic pulmonary fibrosis: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年01月01日 內容資訊: 英文 192 Pages
簡介

2014年10月,FDA同時承認了Esbriet及Ofev作為美國第一個特發性肺纖維化 (IPF) 治療藥。

本報告提供特發性肺纖維化 (IPF) 治療藥趨勢調查,市場定義和概要,疾病定義與診斷,目前治療選擇,處方趨勢,已上市產品簡介,開發後期的開發平台趨勢等彙整資料。

預測:特發性肺纖維化 (IPF)

  • 摘要整理
  • 市場概要、趨勢
  • 調查手法、市場定義
  • Esbriet (pirfenidone)
  • Ofev (nintedanib)
  • 一次調查技術

治療方法:特發性肺纖維化 (IPF)

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢

流行病學:美國、日本、歐盟5國的特發性肺纖維化 (IPF)

  • 摘要整理
  • 資訊來源、分析方法
  • 預測
  • 流行病學者的見解
  • 優勢、規定

上市藥:特發性肺纖維化 (IPF)

  • 摘要整理
  • 產品概要
  • 產品簡介:Esbriet
  • 產品簡介:Ofev

開發平台:特發性肺纖維化 (IPF)

  • 摘要整理
  • 臨床實驗平台概要
  • 標靶治療藥簡介
  • 臨床試驗設計
  • 產品簡介 (開發後期):FG-3019
  • 產品簡介 (開發後期):PRM-151

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC12770

The FDA simultaneously approved both Esbriet and Ofev in October 2014, making them the first treatments specifically approved for IPF in the US.

This report addresses the following questions:

  • How large is the IPF patient population and how many patients are drug-treated across the various severities?
  • What clinical differentiation exists between the two approved products and how does this sway physician behavior?
  • What degree of uptake are Esbriet and Ofev experiencing shortly after their launch?
  • How will the sales trajectories of the two products differ?
  • Now that there are specifically approved treatment options, how will clinical trial design and product positioning for future products change?

TABLE OF CONTENTS

FORECAST: IDIOPATHIC PULMONARY FIBROSIS

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Esbriet (pirfenidone)
  • 5. Ofev (nintedanib)
  • 6. Primary Research Methodology

TREATMENT: IDIOPATHIC PULMONARY FIBROSIS

  • 7. Executive Summary
  • 8. Primary Research Methodology
  • 9. Disease Definition and Diagnosis
  • 10. Patient Segmentation
  • 11. Country Treatment Trees
  • 12. Current Treatment Options
  • 13. Prescribing Trends

EPIDEMIOLOGY: IDIOPATHIC PULMONARY FIBROSIS

  • 14. Executive Summary
  • 15. Sources and Methodology
  • 16. Forecast
  • 17. Epidemiologist Insight
  • 18. Strengths and Limitations

MARKETED DRUGS: IDIOPATHIC PULMONARY FIBROSIS

  • 19. Executive Summary
  • 20. Product Overview
  • 21. Product profile: Esbriet
  • 22. Product profile: Ofev

PIPELINE: IDIOPATHIC PULMONARY FIBROSIS

  • 23. Executive Summary
  • 24. Clinical Pipeline Overview
  • 25. Target Product Profile
  • 26. Clinical Trial Design
  • 27. Product profile (late stage): FG-3019
  • 28. Product profile (late stage): PRM-151
Back to Top